These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 25962998)

  • 21. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
    Xiong C; Yu K; Gao F; Yan Y; Zhang Z
    Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An alternative approach to assess exchangeability of a test treatment and the standard treatment with normally distributed response.
    Tsong Y; Shen M
    J Biopharm Stat; 2007; 17(2):329-38. PubMed ID: 17365227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.
    Wassmer G
    J Biopharm Stat; 2003 Nov; 13(4):585-603. PubMed ID: 14584710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample size planning for survival prediction with focus on high-dimensional data.
    Götte H; Zwiener I
    Stat Med; 2013 Feb; 32(5):787-807. PubMed ID: 22859340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
    Wu PS; Lin M; Chow SC
    J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Point and interval estimation of primary and secondary parameters in a two-stage adaptive clinical trial.
    Liu A; Wu C; Yu KF
    J Biopharm Stat; 2008; 18(2):211-26. PubMed ID: 18327717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A note on effective sample size for constructing confidence intervals for the difference of two proportions.
    Liu GF
    Pharm Stat; 2012; 11(2):163-9. PubMed ID: 22337507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis and importance of statistical power and sample size in empirical scientific research].
    Klimek KM
    Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sample size reassessment in non-inferiority trials. Internal pilot study designs with ANCOVA.
    Friede T; Kieser M
    Methods Inf Med; 2011; 50(3):237-43. PubMed ID: 20213039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.
    Cheng Y; Shen Y
    Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
    Wang YC; Chen G; Chi GY
    J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sample size determination for testing nonequality under a three-treatment two-period incomplete block crossover trial.
    Lui KJ; Chang KC
    Biom J; 2015 May; 57(3):410-21. PubMed ID: 25757940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive sample size calculations in group sequential trials.
    Lehmacher W; Wassmer G
    Biometrics; 1999 Dec; 55(4):1286-90. PubMed ID: 11315085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A modified Wald test for reference scaled assessment of analytical equivalence.
    Weng YT; Tsong Y; Shen M; Wang C
    J Biopharm Stat; 2019; 29(6):1068-1081. PubMed ID: 30829123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corrected profile likelihood confidence interval for binomial paired incomplete data.
    Pradhan V; Menon S; Das U
    Pharm Stat; 2013; 12(1):48-58. PubMed ID: 23296487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.